Medical network - on July 14, the whole body with antibacterial drugs is multiple, treatment of infectious disease categories, have clinical application widely, the characteristics of the variety. In the early 20th century, Fleming invents the penicillin is known as anti-infective drugs, god save the lives of countless people, as a milestone in the medical history of drug. With the rapid growth of China's population, the diet structure and the ecological environment change under the influence of many factors, antibiotic medicines play an immeasurable role.
Penicillium carbon alkene antibiotics (from south drugs) is a kind of atypical beta lactam antibiotics, after the advent of the 1980 s, became a kind of broad spectrum, powerful, low incidence of bacterial drug resistance of drugs.
As domestic "resistance limit, antibiotic market declines obviously, penicillium carbon alkene antibiotics is also one of the category. Although antibiotic market has entered into the phase of the new normal, penicillium carbon alkene antibiotics showed rigid demand, still in cephalosporin such as listed after years of drug resistance of thorny issues, from south drugs rapid growth in the market, become the domestic variety of antibiotics. At this big background, have a lot of companies to join from the south for a class of drugs, and the market prospect with great hope.
After "impedance" low back on track
In recent five years, under the policy of "national impedance" influence, the whole body with antibacterial drugs use linear rising trend has been effectively suppressed, after antibiotics in 2012-2013 hospital market plummeted, its growth rate gradually become the norm. 14 national planning commission and other departments jointly issued the "containing bacteria resistant national action plan (2016-2020)", this is a major measure for national level to implement comprehensive administration of antibiotics.
According to m Intranet China city public hospital chemical medicine terminal (HDM) system data, 2016 key cities for the domestic public hospital antibacterial drugs terminal increased by 7.51% year-on-year in 2015. The growth peak of 22.94% in 2010, by 2010 the growth of the bottom 17.07%, finally presents the direction of the normal at present.
Break through 10 billion scale penicillium carbon alkene antibiotic drugs
At present, our country city public hospital use of antibacterial medicine is divided into 10 subgenera classes, including TOP5 category are penicillium single-agent cephalosporin antibiotics, carbon alkene, compound preparations, compound semi-synthetic penicillin and cephalosporin quinolones. Carbon penicillium domestically listed drugs only six varieties, but occupy 13.96% of the antibacterial drug market, its important role in the clinical and visible.
According to HDM data show that in 2016 key cities for the domestic public hospital carbon alkene drugs in increasing under the macroeconomic regulation and control, year-on-year growth of 14.24% a year, nearly 7% higher than the whole body with antibacterial drugs. Penicillium carbon alkene with strong bactericidal activity than cephalosporins, and become to produce ultra broad spectrum beta lactamase (ESBLs) and cephalosporin enzyme (AmpC) of a class of the most effective antimicrobial multi-resistant bacteria.
So far, global carbon green alkene drugs already on the market with a total of seven. The prescribed drugs are beautiful e.faecalis, than APei south, ertapenem, doni for than Mr South and south five varieties, compound preparations is imine pei's south/west he ding, from south/times he millon. In the original patent expires and generic drug compounds listed under the influence, foreign market sales from peak to plummet.
In 2016, according to relevant data show that global TOP3 penicillium carbon alkene original branded drugs market sales of $1.008 billion, still flat with the previous year, it also brings opportunities for generic drug market.
According to m, according to data from the network in China's urban public hospitals, public hospitals at the county level, urban community center, and in the towns and townships, penicillium carbon alkene antibiotic drugs market breakthrough 10 billion yuan in 2016, overall, imported and domestic breeds has formed against.
2016 domestic hospital TOP3 of penicillium carbon alkene antibiotics, beauty e.faecalis occupied half of the second imine from south west department he who account for 28.08%, the third than APei south accounted for 14.81%, other 5.57%. The beauty e.faecalis systemic anti-infection drugs for the first, illustrates the penicillium carbon alkene antibiotic drugs in our country irreplaceable importance in clinical.
Key city hospital market carbon penicillium alkene antibiotics market share and growth rate
Domestic and imported equal measure
In 2016, according to HDM data analysis domestic hospital penicillium carbon alkene antibiotic market fiercely contested by the 21 company. Imported drugs mainly MSD and daiichi Japan's sumitomo, Japan, South Korea Yungjin Pharm and JW Pharmaceutical Corporation and other six companies, held a 50.40% share of the total.
Domestic companies are shenzhen seaside pharmaceutical co., the sea is Pfizer pharmaceutical, zhengda shine, nolato, group the pharmaceutical industry, simcere 15 companies, occupying 49.60% of the market.
Key city hospital market carbon penicillium alkene antibiotics need competing firms
Chinese culture south drugs after the success of the transformation of generics achievements, has been into rapid development. In anti-infection drugs under the fierce market competition, domestic drugs and imported original preemption penicillium carbon alkene antibiotic drug market. Penicillium domestic carbon alkene antibiotics rapid rise in the short term, mainly because of cephalosporins drug resistance problem for many years, such as listing, and the fourth generation cephalosporin drugs and a new generation of quinolones listed varieties and promotion efforts, in the key cities for the domestic public hospital penicillium carbon alkene antibiotics are exceptionally strong varieties.
Both opportunities and challenges
The global antibiotic resistance increased, and the emergence of superbugs has caused a deterrent to mankind. However in innovative drug research and development under the situation of struggling, the United States through the encourage the development of antibiotics act (GAIN), it certainly inspired national pharmaceutical companies to carry out research and development of new antibiotics.
According to the report, six years from 2006 to 2011 the FDA approved only 111 new drugs, only four just antibiotics; And GAIN, in 2014 the FDA approved 10 class new drugs to fight infection, in 2015 the FDA approved five anti-infection drugs listed, it promoted the global process of class of new drugs to fight infection.
As atypical beta lactam antibiotics used in domestic clinical promotion, Chinese clinical use of penicillium carbon alkene antibiotics have achieved 80% localization, to strengthen the competition mechanism. He's currently only from south times millon daiichi by Japan company exclusive sales, while entering China has more than 10 years, but overall growth is slow, and showed a decline in nearly two years, also did not see the domestic approval registration information.
Penicillium carbon alkene is fight infection in clinical application is the most important varieties resistance, commonly known as "the last line of defense" antibiotics, this kind of drug development is difficult, complex production process, has the high added value, are quite profitable.
Notable is, the domestic oxazole alkane ketone antibiotics rina thiazole amine, ring fat peptide of doxycycline, gump ammonia acyl ring element class of antibiotics for ring element and vancomycin sugar peptide antibiotics in their stead, rather rapid growth of the market, will also be on carbon alkene drugs challenge. |
